ERBB2 and breast neoplasm: Some studies [17] have used integrated analysis of copy number and gene expression in a discovery and validation set of almost 2000 primary breast tumors, in which copy number changes of ZNF703 are very obvious and common in breast tumors, secondary to ERBB2 and CCND1. Therefore, ZNF703 is a new and very important oncogene in breast cancer, and it should be considered as a therapeutic target in ~15% of breast tumors [18].